WuXi PharmaTech Names Steve Yang EVP And COO

(RTTNews) - WuXi PharmaTech (Cayman) Inc. (WX), a pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, announced that Steve Yang has joined the company as Executive Vice President and Chief Operating Officer.

Edward Hu will assume new responsibilities as Chief Investment Officer and remain as Chief Financial Officer.

Before joining WuXi, Yang was Vice President and Head of Asia and Emerging Markets iMed at AstraZeneca, based in Shanghai.

Previously, Yang served as Vice President and Head of Asia R&D at Pfizer based in Shanghai, and as Executive Director and head of Pfizer's global R&D strategic management group based in the United States. Before joining Pfizer, Dr. Yang held a number of leadership positions at IntraBiotics Pharmaceuticals, a U.S.-based biotech company.

The company also announced that Edward Hu will serve as the new Chief Investment Officer in addition to his current role as Chief Financial Officer. Hu will be responsible for companywide investments, including strategic investments in new businesses, corporate venture capital investments, mergers and acquisitions, and joint ventures. He has served as the Company's Chief Operating Officer since January 2008 and as Chief Financial Officer since February 2009.